BRCA-associated breast cancer in young women

被引:264
作者
Robson, M
Gilewski, T
Haas, B
Levin, D
Borgen, P
Rajan, P
Hirschaut, Y
Pressman, P
Rosen, PP
Lesser, ML
Norton, L
Offit, K
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Human Genet, Clin Genet Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[5] N Shore Univ Hosp, Dept Biostat, Manhasset, NY USA
关键词
D O I
10.1200/JCO.1998.16.5.1642
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To delineate the clinical characteristics and outcomes of breast cancer that arises in the setting of a germline BRCA mutation and to compare BRCA-associated breast cancers (BABC) with those that arise in women without mutations. Patients and Methods: We reviewed the clinical records of 91 Ashkenazi Jewish women ascertained during studies of the genetics of early-onset breast cancer. All women underwent testing for the BRCA I mutations 185delAG and 5382insC. After the discovery of BRCA2, 79 women were also tested for the BRCA2 mutation 6174delT, Results: Mutations were identified in 30 women (33%). BABC were less likely to present with stage I disease than cases in women without mutations (27% v 46%), more likely to have axillary nodal involvement (54% v 46%), and more likely to have extensive axillary involvement (25% v 17%). These differences were not statistically significant. BABC were significantly more likely to be histologic grade III (100% v 59%, P = .04) and to be estrogen receptor-negative (70% v 34%, P = .04). In the entire cohort, there were no significant differences between BABC and non-BRCA-associated cancers in 5-year relapse-free survival (65% v 69%, P = not significant [NS]), 5-year event-free survival (57% v 68%, P = NS), or 5-year overall survival. However, among cases diagnosed within 2 years of study entry, there was a trend toward shorter event-free survival in BRCA heterozygotes, but not relapse-free survival. Women with germline BRCA mutations were significantly more likely to develop contralateral breast cancer at 5 years (31% v 4%, P = .0007). Conclusion: BABC present with adverse clinical and histopathologic features when compared with cases not associated with BRCA mutations. However, the prognosis of BABC appears to be similar to that of nonassociated cancer. Further studies of incident cases are necessary to define the independent prognostic significance of germline BRCA mutations. (C) 1998 by American Society of Clinical Oncology.
引用
收藏
页码:1642 / 1649
页数:8
相关论文
共 50 条
[1]  
ALBAIN KS, 1994, MONOGR NATL CANC I, V16, P35
[2]  
ALBANO WA, 1982, CANCER, V50, P360, DOI 10.1002/1097-0142(19820715)50:2<360::AID-CNCR2820500233>3.0.CO
[3]  
2-4
[4]  
ANDERSON DE, 1986, CANCER, V58, P360, DOI 10.1002/1097-0142(19860715)58:2<360::AID-CNCR2820580227>3.0.CO
[5]  
2-F
[6]   RISK-FACTORS IN BREAST-CONSERVATION THERAPY [J].
BORGER, J ;
KEMPERMAN, H ;
HART, A ;
PETERSE, H ;
VANDONGEN, J ;
BARTELINK, H .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) :653-660
[7]   EARLY BREAST-CANCER - PREDICTORS OF BREAST RECURRENCE FOR PATIENTS TREATED WITH CONSERVATIVE SURGERY AND RADIATION-THERAPY [J].
BOYAGES, J ;
RECHT, A ;
CONNOLLY, JL ;
SCHNITT, SJ ;
GELMAN, R ;
KOOY, H ;
LOVE, S ;
OSTEEN, RT ;
CADY, B ;
SILVER, B ;
HARRIS, JR .
RADIOTHERAPY AND ONCOLOGY, 1990, 19 (01) :29-41
[8]   Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2 [J].
Burke, W ;
Daly, M ;
Garber, J ;
Botkin, J ;
Kahn, MJE ;
Lynch, P ;
McTierman, A ;
Offit, K ;
Perlman, J ;
Petersen, G ;
Thomson, E ;
Varricchio, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (12) :997-1003
[9]  
Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO
[10]  
2-Z